Sientra, Inc. (NASDAQ:SIEN) Q4 2022 Results Conference Call March 30, 2023 4:00 PM ET

Company Participants

Oliver Bennett - General Counsel and Chief Compliance Officer

Ron Menezes - President and CEO

Andy Schmidt - CFO

Lisa Rosas - SVP, Marketing

Denise Dajles - SVP, Research and Development, Regulatory and Quality

Conference Call Participants

Alex Nowak - Craig-Hallum Capital Group

Jon Block - Stifel

Anthony Vendetti - Maxim Group

Operator

Good day. And welcome to the Sientra Incorporated Fourth Quarter and Full Year 2022 Earnings Conference Call. All participants will be in a listen only mode [Operator Instructions]. after today’s presentation, there will be an opportunity to ask questions. Please note this event is being recorded.

I would now like to turn the conference over to your host, Mr. Oliver Bennett, Sientra's General Counsel and Chief Compliance Officer. Mr. Bennett, you may begin.

Oliver Bennett

Thank you. Good afternoon. We are pleased that you could join us on today's call to discuss Sientra's fourth quarter and full year 2022 financial results and business update. On our call today, we have Ron Menezes, Sientra's President and Chief Executive Officer; Andy Schmidt, Sientra's Chief Financial Officer; Lisa Rosas, Sientra's Senior Vice President of Marketing; and Dr. Denise Dajles, Sientra's Senior Vice President of Research and Development, Regulatory and Quality. As reported earlier today, we have achieved another record quarter and year for Sientra. Our Q4 revenue of $25.1 million is the highest quarterly revenue in the history of the company and represents almost 100% growth in our breast product business from our pre-pandemic high of $12.8 million in Q4 2019. While we see continued strength in our core implant and expander portfolio, we have also taken steps to accelerate our growth with the commercial launch of our Viality fat transfer system and our recently announced partnership with Aziyo Biologics. As Ron will provide more detail on, these new products dramatically increase our total addressable market to over $1 billion in the United States alone, while also enhancing our pathway to profitability.

Of course, I must remind everyone that in our remarks today, we will include forward-looking statements in our prepared remarks and in response to any questions you may ask. These forward-looking statements are based on management's current assumptions and expectations of future events and trends. Our actual results may differ materially from those expressed in or implied by those forward-looking statements. The company undertakes no obligation to update or review any estimate, projection or forward-looking statement. For a more detailed discussion of the company's risks and uncertainties, I would refer you to our SEC filings, including our Form 10-K and Form 10-Q available on the company's Web site. With that, I'll turn the call over to our President and Chief Executive Officer, Ron, to comment on our continued exemplary growth this past quarter and provide a look ahead at 2023 and beyond.